Pliant Therapeutics logo

Pliant Therapeutics Funding & Investors

Redwood City, CA

Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases. By harnessing the therapeutic potential of integrin biology and TGF-β modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery. Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.

pliantrx.com

Total Amount Raised: $694,945,152

Pliant Therapeutics Funding Rounds

  • Post Ipo Equity

    $287,500,000

  • Post Ipo Equity

    $200,000,000

  • Series C

    $100,445,146

    Series C Investors

    Adveq
    Eventide
    Logos Capital
    Novartis Medical Nutrition
    Redmile Group
    Menlo Ventures
    S-Cubed Capital
    Agent Capital
    Cormorant Asset Management
    Farallon Capital Management
    Surveyor Capital
    Cowen
  • IPO

    Unknown

  • Series B

    $62,000,000

    Series B Investors

    Eventide
    Adveq
    Menlo Ventures
    Agent Capital
    S-Cubed Capital
    Cowen
  • Series A

    $45,000,000

    Series A Investors

    pH Pharma
    Third Rock Ventures
Funding info provided by Diffbot.